Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
Mult Scler Relat Disord
; 49: 102777, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1036334
ABSTRACT
We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Monoclonales Humanizados
/
COVID-19
/
Anticuerpos Antivirales
/
Esclerosis Múltiple
Tipo de estudio:
Reporte de caso
/
Estudio experimental
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Mult Scler Relat Disord
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.msard.2021.102777
Similares
MEDLINE
...
LILACS
LIS